Loading...
Loading...
According to a research report this morning, Piper Jaffray initiated an Overweight rating and a $10 PT on Supernus Pharmaceuticals
SUPN as the up-and-coming pharmaceutical company introduced two impressive Central Nervous System therapies.
Piper Jaffray explained, “Supernus is an emerging specialty pharmaceutical company that is leveraging its well-established expertise in extended- and modified-release drug delivery technologies to develop and commercialize next-generation oral therapies for the treatment of a variety of diseases of the central nervous system (CNS). We could see two FDAapproved extended-release (ER) therapies, namely ER topiramate formulation SPN-538 and ER oxcarbazepine formulation SPN-804, for the treatment of epilepsy before the end of 2012.”
Supernus Pharmaceuiticals closed Friday at $5.94.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in